ArticleJournal of the American Chemical Society2014
An unusual ligand coordination gives rise to a new family of rhodium metalloinsertors with improved selectivity and potency.
Article in Journal of the American Chemical Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Mitochondria-targeting cyclometallated rhodium(iii) complexes appended with two rhodamine units as Type I photosensitisers for bioimaging and photocytotoxicity applications by inducing pyroptosis.Chemical science · 2026Article
- Recent Advances in Anticancer Research of Osmium and Rhodium Complexes.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2025Review
- Activation of the cGAS-STING pathway by a mitochondrial DNA-targeted emissive rhodium(iii) metallointercalator.Chemical science · 2023Article
- Reversible PtChemical science · 2021Article
- AnChemical science · 2020Article
- In vivo anticancer activity of a rhodium metalloinsertor in the HCT116 xenograft tumor model.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- A Family of Rhodium Complexes with Selective Toxicity toward Mismatch Repair-Deficient Cancers.Journal of the American Chemical Society · 2018Article
- A Rhodium-Cyanine Fluorescent Probe: Detection and Signaling of Mismatches in DNA.Journal of the American Chemical Society · 2017Article
- A Ruthenium(II) Complex as a Luminescent Probe for DNA Mismatches and Abasic Sites.Inorganic chemistry · 2017Article
- Rhodium metalloinsertor binding generates a lesion with selective cytotoxicity for mismatch repair-deficient cells.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Targeting DNA Mismatches with Rhodium Metalloinsertors.Inorganica chimica acta · 2016Article
- [Ru(Me4phen)2dppz](2+), a Light Switch for DNA Mismatches.Journal of the American Chemical Society · 2016Article
- A monofunctional platinum complex coordinated to a rhodium metalloinsertor selectively binds mismatched DNA in the minor groove.Inorganic chemistry · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Rhodium metalloinsertors are octahedral complexes that bind DNA mismatches with high affinity and specificity and exhibit unique cell-selective cytotoxicity, targeting mismatch repair (MMR)-deficient cells over MMR-proficient cells. Here we describe a new generation of metalloinsertors with enhanced biological potency and selectivity, in which the complexes show Rh-O coordination. In particular, it has been found that both Δ- and Λ-[Rh(chrysi)(phen)(DPE)](2+) (where chrysi =5,6 chrysenequinone diimmine, phen =1,10-phenanthroline, and DPE = 1,1-di(pyridine-2-yl)ethan-1-ol) bind to DNA containing a single CC mismatch with similar affinities and without racemization. This is in direct contrast with previous metalloinsertors and suggests a possible different binding disposition for these complexes in the mismatch site. We ascribe this difference to the higher pKa of the coordinated immine of the chrysi ligand in these complexes, so that the complexes must insert into the DNA helix with the inserting ligand in a buckled orientation; spectroscopic studies in the presence and absence of DNA along with the crystal structure of the complex without DNA support this assignment. Remarkably, all members of this new family of compounds have significantly increased potency in a range of cellular assays; indeed, all are more potent than cisplatin and N-methyl-N'-nitro-nitrosoguanidine (MNNG, a common DNA-alkylating chemotherapeutic agent). Moreover, the activities of the new metalloinsertors are coupled with high levels of selective cytotoxicity for MMR-deficient versus proficient colorectal cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.